Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jun;71(6):995-1005.
doi: 10.1002/mus.28383. Epub 2025 Feb 27.

Characteristics of Patients With Spinal Muscular Atrophy Who Have Switched Treatments: A Multi-Center Experience in the United Kingdom

Emer O'Reilly  1 , Georgia Stimpson  1 , Annemarie Rohwer  1 , Evelin Milev  1 , Amy Wolfe  1 , Giovanni Baranello  1   2 , Francesco Muntoni  1   2 , Mariacristina Scoto  1   2 ; SMA REACH UK Network
Affiliations
Multicenter Study

Characteristics of Patients With Spinal Muscular Atrophy Who Have Switched Treatments: A Multi-Center Experience in the United Kingdom

Emer O'Reilly et al. Muscle Nerve. 2025 Jun.

Abstract

Introduction/aims: The evolving landscape of spinal muscular atrophy (SMA) treatment in the United Kingdom allows patients to switch, with health authority approval, from one treatment to another. This retrospective analysis explores the characteristics of pediatric patients across the United Kingdom who switched between available therapies that included nusinersen, risdiplam, and onasemnogene abeparvovec (OA).

Methods: Demographic data were collected, along with indicators of disease severity and motor function scores for all pediatric patients registered with the SMA REACH UK database who received nusinersen or risdiplam as initial treatments.

Results: Data were available for 375 patients across 19 sites. In total, 289 patients received nusinersen (of whom 21% switched to risdiplam and 16% to OA), and 86 patients received risdiplam (of whom 5% switched to OA). The top reported reasons for treatment changes were as follows: nusinersen to risdiplam: related to spine complexity (28/52), other difficulties related to administration (23/52); nusinersen to OA: parent preference (19/36), bridging to OA (14/36); risdiplam to OA: parent preference (2/2). After switching, no patients requested to go back to the initial treatment. No patients demonstrated deterioration beyond the expected disease trajectory prior to switching.

Discussion: The availability of treatments in the United Kingdom has fundamentally influenced treatment choices, but deterioration in a treatment was not identified as a factor in switching treatments. Further work will be needed to investigate the long-term trajectory of these patients.

Keywords: nusinersen; onasemnogene abeparvovec; risdiplam; spinal muscular atrophy; switching therapy.

PubMed Disclaimer

References

    1. S. M. Hoy, “Nusinersen: First Global Approval,” Drugs 77 (2017): 473–479.
    1. E. Mercuri, N. Deconinck, E. S. Mazzone, et al., “Safety and Efficacy of Once‐Daily Risdiplam in Type 2 and Non‐Ambulant Type 3 Spinal Muscular Atrophy (SUNFISH Part 2): A Phase 3, Double‐Blind, Randomised, Placebo‐Controlled Trial,” Lancet Neurology 21 (2022): 42–52, https://doi.org/10.1016/S1474‐4422(21)00367‐7.
    1. R. S. Finkel, E. Mercuri, B. T. Darras, et al., “Nusinersen Versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy,” New England Journal of Medicine 377 (2017): 1723–1732, https://doi.org/10.1056/NEJMoa1702752.
    1. G. Baranello, B. T. Darras, J. W. Day, et al., “Risdiplam in Type 1 Spinal Muscular Atrophy,” New England Journal of Medicine 384 (2021): 915–923, https://doi.org/10.1056/NEJMoa2009965.
    1. J. W. Day, R. S. Finkel, C. A. Chiriboga, et al., “Onasemnogene Abeparvovec Gene Therapy for Symptomatic Infantile‐Onset Spinal Muscular Atrophy in Patients With Two Copies of SMN2 (STR1VE): An Open‐Label, Single‐Arm, Multicentre, Phase 3 Trial,” Lancet Neurology 20 (2021): 284–293, https://doi.org/10.1016/S1474‐4422(21)00001‐6.

Publication types

LinkOut - more resources